Francoise-Barre-Sinoussi: a legend


http://mosaicscience.com/story/francoise-barre-sinoussi




An interesting article that is full of life, yet poignant, considering the lives lost to the disease and the impact of a discovery on the strained relationships between scientists. A terrific article describing the life and work of Francoise Barre-Sinoussi, the co-discoverer of the HIV virus.

Comments

Post a Comment

Popular posts from this blog

Coronavirus and Vaccine Development

Coronavirus Vaccine Update: In addition to VBI Vaccines Inc. (Ottawa, Canada), the following firms are as of 27 March 2020 beginning Phase 1 testing Phase I vaccine candidates   Company:  Moderna Vaccine candidate:  mRNA-1273 Details:  Moderna is the Massachusetts-based biotech company behind mRNA-1273, a vaccine candidate developed using prior studies of related coronaviruses, such as severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS). Study Design:  A Phase 1, open-label, dose-ranging clinical trial of 45 healthy participants between 18-55 years old Institution:   Kaiser Permanente Washington Health Research Institute Status:  Recruiting completed 19 March 2020 ClinicalTrials.gov Identifier:   NCT04283461 Funding:  NIAID   Company:  CanSino Biologics Vaccine candidate:  Ad5-nCoV Details:  China’s CanSino Biologics has developed a recombinant novel coronavirus vaccine that incorporates the adenovirus type 5 vector (Ad5). Study Design:  A Phase 1 cl
Read more

More interesting discoveries from the RV144 trial (Tweeted by ‏@TweetSosa )

A recent paper by a multi-center group looking into the famous "31.2% vaccine efficacy" study (RV144 trial) shows interesting features associated with this protection against HIV-1. Shuying Li looked at vaccine-induced Fc receptor-mediated antibody function and in this paper, show that a single nucleotide polymorphism in the FcR-encoding genes is strongly associated with protection. Individuals with a  SNP (rs114945036) carrying CC in this SNP had a vaccine efficacy of 15% while those with a CT or TT had a vaccine efficacy of 91% against HIV-1 subtype CRF01_AE with a lysine at position 169 (169K) in the V2 loop. RV144 is a treasure trove of discoveries. The world is eagerly waiting for more data and a cure! This has been tweeted: Joe L Sosa Jr  ‏ @ TweetSosa     21m In Study of HIV Vaccine Trial Subjects, Genotype Defines Subsets with Strong and Weak Response http:// dlvr.it/6gQWts
Read more